review Open AccessTop 1% cited
mRNA vaccines manufacturing: Challenges and bottlenecks
Vaccine · 2021 · Vol. 39(16) · pp. 2190–2200
Sara Sousa Rosa(Institute for Biotechnology and Bioengineering)D.M.F. Prazeres(University of Lisbon)Ana M. Azevedo✉(Institute for Biotechnology and Bioengineering)Marco P. C. Marques✉(University College London)
RNA Interference and Gene DeliveryViral gastroenteritis research and epidemiologyImmunotherapy and Immune ResponsesVaccinationManufacturing processMedicineBusinessBiotechnologyVirologyBiology
MeSH terms
COVID-19mRNA VaccinesHumansRNA, MessengerVaccines, SyntheticPandemics
Funding
- Engineering and Physical Sciences Research Council
- Fundação para a Ciência e a Tecnologia
Citations
488
FWCI
27.59
field-weighted impact
References
123
Percentile
100%
vs. same field & year
Citations per year
References
mRNA-based therapeutics — developing a new class of drugs
Nature Reviews Drug Discovery · 2014 · 2,333 citations
The mRNA 5′ cap-binding protein eIF4E and control of cell growth
Current Opinion in Cell Biology · 1998 · 669 citations
mRNA vaccines — a new era in vaccinology
Nature Reviews Drug Discovery · 2018 · 4,317 citations
New Vaccine Technologies to Combat Outbreak Situations
Frontiers in Immunology · 2018 · 588 citations
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Vaccine · 2019 · 456 citations
The COVID-19 vaccine development landscape
Nature Reviews Drug Discovery · 2020 · 2,078 citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine · 2020 · 15,281 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.